Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-09-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-021-00328-3 |
| _version_ | 1797428252384428032 |
|---|---|
| author | Luiza N. Weis Sara M. Tolaney Carlos H. Barrios Romualdo Barroso-Sousa |
| author_facet | Luiza N. Weis Sara M. Tolaney Carlos H. Barrios Romualdo Barroso-Sousa |
| author_sort | Luiza N. Weis |
| collection | DOAJ |
| description | Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved the use of three different agents for tumor-agnostic treatment: pembrolizumab (for patients with microsatellite instability or high tumor mutational burden) and larotrectinib and entrectinib (both for use in patients harboring tumors with NTRK fusions). Importantly, the genomic alterations targeted by these agents are uncommon or rare in breast cancer, and little information exists regarding their efficacy in advanced breast cancer. In this review, we discuss the prevalence of these targets in breast cancer, their detection methods, the clinical characteristics of patients whose tumors have these alterations, and available data regarding the efficacy of these agents in breast cancer. |
| first_indexed | 2024-03-09T08:55:46Z |
| format | Article |
| id | doaj.art-99ddf49ec2724697925a230a9dd6ae2f |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-09T08:55:46Z |
| publishDate | 2021-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-99ddf49ec2724697925a230a9dd6ae2f2023-12-02T13:09:58ZengNature Portfolionpj Breast Cancer2374-46772021-09-01711910.1038/s41523-021-00328-3Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?Luiza N. Weis0Sara M. Tolaney1Carlos H. Barrios2Romualdo Barroso-Sousa3Instituto de Ensino e Pesquisa Hospital Sírio-LibanêsDepartment of Medical Oncology, Dana-Farber Cancer InstituteLACOG, OncoclinicasInstituto de Ensino e Pesquisa Hospital Sírio-LibanêsAbstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved the use of three different agents for tumor-agnostic treatment: pembrolizumab (for patients with microsatellite instability or high tumor mutational burden) and larotrectinib and entrectinib (both for use in patients harboring tumors with NTRK fusions). Importantly, the genomic alterations targeted by these agents are uncommon or rare in breast cancer, and little information exists regarding their efficacy in advanced breast cancer. In this review, we discuss the prevalence of these targets in breast cancer, their detection methods, the clinical characteristics of patients whose tumors have these alterations, and available data regarding the efficacy of these agents in breast cancer.https://doi.org/10.1038/s41523-021-00328-3 |
| spellingShingle | Luiza N. Weis Sara M. Tolaney Carlos H. Barrios Romualdo Barroso-Sousa Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? npj Breast Cancer |
| title | Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? |
| title_full | Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? |
| title_fullStr | Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? |
| title_full_unstemmed | Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? |
| title_short | Tissue-agnostic drug approvals: how does this apply to patients with breast cancer? |
| title_sort | tissue agnostic drug approvals how does this apply to patients with breast cancer |
| url | https://doi.org/10.1038/s41523-021-00328-3 |
| work_keys_str_mv | AT luizanweis tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer AT saramtolaney tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer AT carloshbarrios tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer AT romualdobarrososousa tissueagnosticdrugapprovalshowdoesthisapplytopatientswithbreastcancer |